BVCT Update
20/04/2006 8:02am
UK Regulatory
RNS Number:7083B
Medical Marketing Int'l Group PLC
20 April 2006
For Immediate Release 20 April 2006
MMI agreement with Bioscience VCT becomes unconditional
Medical Marketing International Group plc ("MMI") (AIM: MMG), the Cambridge, UK-
based pharmaceutical development company focussed on cancer and infection, today
announces that it has reached unconditional agreement with Bioscience VCT plc
("the VCT") and Octopus Asset Management Limited ("Octopus") whereby MMI has
sold its interests in the VCT to enable it to focus on its core business of
developing its portfolio of therapeutics.
MMI announced on 9 March 2006 that it had reached conditional agreement with VCT
and Octopus whereby MMI would cease to provide services to VCT and forego its
carried interest in the VCT. In return, the VCT and Octopus had agreed to:
* Pay MMI an undisclosed sum
* Indemnify, keep indemnified and hold MMI harmless from and against
liabilities arising out of and/or in connection with the services, except for
any investment decisions made by the VCT after relying solely on due diligence
performed by MMI
* Table a resolution at the Annual General Meeting of the VCT for the
purpose of considering changing the company name to exclude the word
" Bioscience " (which is associated with MMI) with a recommendation from
directors of the VCT for shareholders to vote in favour of the resolution
Following the passing of the resolution at yesterday's AGM of the VCT to change
the name of the VCT from Bioscience VCT to Hygea VCT plc, the agreement between
MMI, Octopus and VCT has become unconditional.
David Best Chairman of MMI commenting on this announcement said: "This agreement
now enables MMI to focus solely on its successful core business of developing
and commercialising its expanding portfolio of therapies for cancer and
infection."
For further information, please contact:
David Best ?c=8211 Executive Chairman
MMI Group Tel: +44 (0)1223 477677
www.mmigroup.co.uk
Lisa Baderoon / Rebecca Skye Dietrich
Buchanan Communications Tel: +44 (0)20 7466 5000
lisab@buchanan.uk.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRUKAWRNVRSAAR